Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTIVATE: modern treatment of inhibitor-positive patients with hemophilia A
2019-003427-38Phase 4Active
- Sponsor
- Hangzhou Ruiming Biotechnology
- Start
- Oct 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Octanate, von Willebrand factor concentrate, simoctocog alfa, emicizumab and coagulation factor VIIa in hemophilia A (2 arms), sponsored by Hangzhou Ruiming Biotechnology. Started Oct 2019; status: active.
02
Drugs
Octanatevon Willebrand factor concentratesimoctocog alfaemicizumabcoagulation factor VIIa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2019-003427-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003427-38.